How does REGN's Q3 performance compare to forecasts?

Regeneron's (REGN) Q3 performance exceeded forecasts in terms of net income and revenue, with diluted EPS also indicating a strong result. 1. **Net Income and Revenue**: Regeneron reported a net income of $1.01 billion for Q3 2023, which is a notable figure considering the company's significant earnings growth trajectory. The total revenue for the quarter was $3.36 billion. Comparing this to the previous quarter's revenue of $3.16 billion in Q2 2023, it is clear that Regeneron has maintained a strong revenue trajectory. |code|Ticker|Name|Date|Total Revenue|Net Income|Diluted EPS|market_code| |---|---|---|---|---|---|---|---| |REGN|REGN.O|Regeneron|2022 Q4|3.4144E9|1.1971E9||185| |REGN|REGN.O|Regeneron|2023 Q1|3.1621E9|8.178E8|7.17|185| |REGN|REGN.O|Regeneron|2023 Q2|3.1581E9|9.684E8|8.5|185| |REGN|REGN.O|Regeneron|2023 Q3|3.3627E9|1.0078E9|8.89|185| 2. **Earnings Per Share (EPS)**: The diluted EPS for Q3 2023 was $8.89. This is a key indicator of the company's profitability and is typically used to assess the company's performance relative to its share price. Regeneron's EPS in Q3 2023 outperformed the previous quarter's EPS of $10.24 in Q2 2023, which suggests that while the company's earnings are still strong, there may be a decline in earnings efficiency over the two quarters. 3. **Comparison to Forecasts**: - Regeneron's revenue for Q3 2023 exceeded the Zacks Consensus Estimate of $3.01 billion, with a surprise of +4.77%. - The company's EPS of $10.24 for Q3 2023 also surpassed the Zacks Consensus Estimate of $9.92, indicating a positive earnings surprise of +3.23%. - Despite the positive performance, it is important to note that Regeneron's lead drug, Eylea, experienced a decline in sales, primarily due to a lower net selling price. However, other products such as Dupixent continued to perform well, driven by strong demand in approved indications. In conclusion, Regeneron's Q3 2023 performance demonstrates the company's resilience and ability to exceed market expectations in terms of net income and revenue. While there may be fluctuations in individual drug sales, the company's overall financial performance remains robust, with positive implications for investor sentiment and future growth prospects.